Michael Andreeff
Affiliations: | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Virology Biology, Oncology, Cell BiologyGoogle:
"Michael Andreeff"Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pourebrahim R, Heinz Montoya R, Alaniz Z, et al. (2023) Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage. Cell Death & Disease. 14: 371 |
| Carter BZ, Mak PY, Muftuoglu M, et al. (2023) Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood |
| Pourebrahim R, Montoya RH, Alaniz Z, et al. (2023) Mdm2/p53 levels in bone marrow mesenchymal stromal cells is essential for maintaining the hematopoietic niche in response to DNA damage. Research Square |
| Ganan-Gomez I, Yang H, Ma F, et al. (2022) Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine |
| Post SM, Ma H, Malaney P, et al. (2021) AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill -ITD acute myeloid leukemia. Haematologica |
| Nishida Y, Zhao R, Heese LE, et al. (2021) Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia |
| Zeng Z, Ly C, Daver N, et al. (2021) High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. Annals of Hematology |
| Lee J, Khan DH, Hurren R, et al. (2021) Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. Blood |
| Carter BZ, Mak PY, Tao W, et al. (2020) Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica |
| Yuan B, El Dana F, Ly S, et al. (2020) Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway. Plos One. 15: e0242809 |